Charles River Laboratories presents with optimistic growth expectations that seem a stretch given the business's current performance. See why CRL stock is a Hold.

Charles River has been riding rough waters in 2024, and as the CRO’s CEO predicted, the third quarter proved no exception. | ...

One of Massachusetts' major life science companies, Charles River Laboratories Inc., has revealed new details on its ongoing cost-savings initiatives, stating in an earnings call that it’s “already ...

Farther Finance Advisors LLC lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free ...

Charles River Laboratories, a Wilmington, Mass., pharma services giant, is closing a Skokie office that will result in the ...

Charles River Laboratories Intl ( (CRL)) has released its Q3 earnings. Here is a breakdown of the information Charles River Laboratories Intl presented to its investors. Charles River Laboratories ...

Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and ...

Dozens of researchers across Canada have joined a growing chorus of voices urging the federal government to halt the ...

By Sam Boughedda Charles River Laboratories (NYSE:CRL) shares plummeted over 14% Wednesday after the company said in its latest earnings report that it has received a subpoena from ...

Please stand by, we’re about to begin. Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories Third Quarter 2024 Earnings Conference Call. This call is ...